Trial Profile

A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleotide (ASO) against chronic Hepatitis B (CHB) followed by chronic Hepatitis B targeted immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide analogue (NA) therapy.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bepirovirsen (Primary) ; ChAd155 hIi HBV (Primary) ; HBc HBs/AS01B 4 (Primary) ; MVA HBV (Primary)
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Acronyms TH HBV ASO-001
Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

04 Apr 2025 Planned End Date changed from 11 Feb 2026 to 16 Jun 2025.
04 Apr 2025 Planned primary completion date changed from 11 Feb 2026 to 16 Jun 2025.
13 Sep 2023 Planned End Date changed from 26 Jan 2026 to 11 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com